©2023 by MycoMedica
Redefining Mental Wellness: Bringing together Tradition and Technology to Improve the Lives of our Patients
Whole Human Health for all
The Future of
We strive to give mental health patients their lives back by delivering safe and efficacious, psilocybin-based treatments.
MycoMedica Life Sciences is a pioneering biopharmaceutical company whose mission is to revolutionize the development of a new class of safe and efficacious psychedelic medications for mental health and neurodegenerative disorders. We believe that every individual deserves access to quality healthcare. We are committed to ensuring that no one is left behind in their pursuit of whole human health.
Creating a New Paradigm
We combine data-driven science and wisdom to create potentially transformational treatments.
We are conducting non-clinical studies to understand the neurochemistry and behavioral pharmacology of psilocybin in animals; and human clinical studies to test the safety and efficacy of low-dose psilocybin treatments in patients suffering from several mental health conditions and central nervous system disorders.
We have prioritized a women's health issue, Premenstrual Dysphoric Disorder (PMDD), as our first of several planned clinical trials.
We are committed to researching the science underlying 5HT2A receptor-targeted treatments for various neuropsychiatric conditions. We aspire to drive clinically meaningful improvements, resulting in better outcomes for patients. With an exceptional team of experienced drug development professionals, we are pioneering the application of psychedelics, such as psilocybin, for the treatment of various neuropsychiatric conditions including Premenstrual Dysphoric Disorder (PMDD), Obsessive Compulsive Disorder (OCD), Opioid Use Disorder (OUD), and potentially neurodegenerative conditions such as Parkinson´s Disease (PD).